Vitro activity of imipenem-relebactam against gram-negative eskape pathogens isolated by clinical laboratories in the United States in 2015 (results from the smart global surveillance program)

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 6, 2017, Pages

  Lob, Sibylle H ^a   Hackel, Meredith A ^a   Kazmierczak, Krystyna M ^a   Young, Katherine ^b   Motyl, Mary R ^b   Karlowsky, James A ^c   Sahm, Daniel F ^a  

^a International Health Management Associates Inc   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Eskape pathogens; Imipenem; Relebactam; Smart; Surveillance

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; RELEBACTAM; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; MK-7655;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BROTH DILUTION; CLINICAL LABORATORY; ENTEROBACTER; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; UNITED STATES; DRUG EFFECTS; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; IMIPENEM; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 85019660287     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02209-16     Document Type: Article

References (25)

1. Livermore DM. 2001. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 47:247-250. https://doi.org/10.1093/jac/47.3.247.
2. Rodriguez-Martinez Poirel L, Nordmann P. 2009. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:4783- 4788. https://doi.org/10.1128/AAC.00574-09.
3. Riera E, Cabot G, Mulet X, Garcia-Castillo M, del Campo R, Juan C, Canton R, Oliver A. 2011. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenemand doripenem. J Antimicrob Chemother 66:2022-2027. https://doi.org/10.1093/jac/dkr232.
4. Castanheira M, Mills JC, Farrell DJ, Jones RN. 2014. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidimenonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother 58:6844-6850. https://doi.org/10.1128/AAC.03681-14.
5. Toussaint KA, Gallagher JC. 2015. β-lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother 49:86-98. https://doi.org/10.1177/1060028014556652.
6. Jacoby GA. 2009. AmpC β-lactamases. Clin Microbiol Rev 22:161-182. https://doi.org/10.1128/CMR.00036-08.
7. Drawz SM, Papp-Wallace KM, Bonomo RA. 2014. New beta-lactamse inhibitors: A therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835-1846. https://doi.org/10.1128/AAC.00826-13.
8. Olsen I. 2015. New promising β-lactamase inhibitors for clinical use. Eur J Clin Microbiol Infect Dis 34:1303-1308. https://doi.org/10.1007/s10096-015-2375-0.
9. Livermore DM, Warner M, Mushtaq S. 2013. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286 -2290. https://doi.org/10.1093/jac/dkt178.
10. Young K, Raghoobar SL, Hairston NN, Painter RE, Racine F, Dorso KL, Park Y-W, Ogawa AM, Wisniewski D, Hermes J, Blizzard TA, Hammond ML, Motyl MR. 2010. In vitro activity of the class A and C-lactamase inhibitor MK-7655. ICAAC 2010, Boston, MA, poster F1-2139.
11. Rice LB. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079 -1081. https://doi.org/10.1086/533452.
12. Rice LB. 2010. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 31(Suppl 1):S7-S10. https://doi.org/10.1086/655995.
13. Pogue JM, Kaye KS, Cohen DA, Marchaim D. 2015. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clin Microbiol Infect 21:302-312. https://doi.org/10.1016/j.cmi.2014.12.025.
14. Bodro M, Sabé N, Tubau F, Lladó L, Baliellas C, Roca J, Cruzado JM, Carratalà J. 2013. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation 96:843- 849. https://doi.org/10.1097/TP.0b013e3182a049fd.
15. Patel TW, Nagel JL. 2015. Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs. J Clin Microbiol 53:201-205. https://doi.org/10.1128/JCM.03057-14.
16. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. 2010. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 54:3717-3722. https://doi.org/10.1128/AAC.00207-10.
17. Boucher HW, Talbot GH, Bradley JS, Edwards JE Jr, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Society of America. Clin Infect Dis 48: 1-12. https://doi.org/10.1086/595011.
18. Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. 2013. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 6:1335-1346. https://doi.org/10.3390/ph6111335.
19. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. 2015. Activity of imipenem with relebactam against Gramnegative pathogens from New York City. Antimicrob Agents Chemother 59:5029 -5031. https://doi.org/10.1128/AAC.00830-15.
20. Davies TA, Queenan AM, Morrow BJ, Shang W, Amsler K, He W, Lynch AS, Pillar C, Flamm RK. 2011. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermentors from the USA in 2007-09. J Antimicrob Chemother 66:2298 -2307. https://doi.org/10.1093/jac/dkr290.
21. Lob SH, Hoban DJ, Sahm DF, Badal RE. 2016. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 47:317-323. https://doi.org/10.1016/j.ijantimicag.2016.01.015.
22. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26th informational supplement. M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 10th ed. Approved standard M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
24. Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF. 2016. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-Avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 60:4743- 4749. https://doi.org/10.1128/AAC.00220-16.
25. Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF. 2015. Trends in susceptibility of Escherichia coli from intra-Abdominal infections to ertapenem and comparators in the United States according to data from the SMART Program, 2009 to 2013. Antimicrob Agents Chemother 59: 3606 -3610. https://doi.org/10.1128/AAC.05186-14.